During the corresponding time, Cytosorbents Corporation recorded a revenue increase by 9.29 % year on year, sequentially revenue grew by 18.49 %. While revenue at the Cytosorbents Corporation's corporate clients
Cytosorbents's Comment on Sales, Marketing and Customers
The Company serves customers in France for cardiac surgery applications under an agreement with Terumo, which expired on January 1, 2025, but remains in effect during ongoing negotiations. In March 2021, the Company entered a global co-marketing agreement with B. Braun Avitum AG to promote CytoSorb alongside B. Braun's OMNI continuous blood purification platform and OMNIset Plus bloodline set, excluding the U.S. market. The CytoSorb adsorber is utilized in critical care for extracorporeal removal of cytokines and inflammatory mediators. The Company consults with Scientific Advisory Board members for expert opinions in basic science, critical care medicine, and cardiac surgery. It pays a perpetual royalty of 3% on sales of its technology to ROKK, LLC, covering products such as CytoSorb, VetResQ, ECOS-300CY, DrugSorb, and DrugSorb-ATR. Additionally, under a Settlement Agreement with Purolite, the Company holds exclusive rights to use patented technology related to adsorbent polymers for 18 years, with royalty payments ranging from 2.5% to 5% on certain product sales.
In an era where digital presence is paramount for growth and engagement, CytoSorbents Corporation, a leading medical technology company specializing in critical care, has taken a significant leap forward by unveiling a newly redesigned and unified website. This initiative not only reflects the company’s commitment to innovation but also emphasizes its mission of saving lives through collaboration themes encapsulated in the tagline, Working to Save Lives Together. A Unified Brand Identity: Bridging Corporate and Product LinesPreviously, CytoSorbents operated with separate websites catering to its corporate identity and its product offerings. This bifurcation can often confuse stakeholders; however, this rec...
CytoSorbents Secures Regulatory Approval for CytoSorb Blood Purification Therapy in Taiwan CytoSorbents Corporation, a critical care immunotherapy leader specializing in blood purification, has announced that its flagship product, CytoSorb, has received regulatory approval from the Taiwan Food and Drug Administration (TFDA). This approval marks a significant milestone for the company, enabling it to introduce a powerful blood purification therapy to critically ill patients and those undergoing cardiac surgery in Taiwan. Overview of CytoSorb Technology CytoSorb is an advanced extracorporeal blood purification therapy designed to reduce the blood s excessive levels of proteins, cytokines, and other toxic subst...
This innovative technology, designed and patented by CytoSorbents Corporation, focuses on reducing the risk factors linked with organ failure and dysfunction following a heart transplant. These risk factors include a high inflammatory state, potential damage caused by ischemia and reperfusion injury, and complications due to the transplantation procedure itself.The primary using CytoSorb therapy during heart transplants is to control the levels of inflammatory mediators in the blood. Initially, a wave of these mediators, known as a ‘cytokine storm’, can often result in severe systemic inflammation, leading to potentially life-threatening multi-organ failure. With the use of CytoSorb, in effect, work was...
Cytosorbents’s Comment on Sales, Marketing and Customers
The Company serves customers in France for cardiac surgery applications under an agreement with Terumo, which expired on January 1, 2025, but remains in effect during ongoing negotiations. In March 2021, the Company entered a global co-marketing agreement with B. Braun Avitum AG to promote CytoSorb alongside B. Braun's OMNI continuous blood purification platform and OMNIset Plus bloodline set, excluding the U.S. market. The CytoSorb adsorber is utilized in critical care for extracorporeal removal of cytokines and inflammatory mediators. The Company consults with Scientific Advisory Board members for expert opinions in basic science, critical care medicine, and cardiac surgery. It pays a perpetual royalty of 3% on sales of its technology to ROKK, LLC, covering products such as CytoSorb, VetResQ, ECOS-300CY, DrugSorb, and DrugSorb-ATR. Additionally, under a Settlement Agreement with Purolite, the Company holds exclusive rights to use patented technology related to adsorbent polymers for 18 years, with royalty payments ranging from 2.5% to 5% on certain product sales.
Sources:
Cytosorbents Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cytosorbents Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Cytosorbents Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1.45 %